XOMA Corp


Looking Ahead of Wall Street: Tesla Motors Inc (TSLA), Xoma Corp (XOMA), Walt Disney Co (DIS), Intercept Pharmaceuticals Inc (ICPT)

Wall Street has an exciting week ahead as earnings season continues to roll on with Tesla Motors Inc (NASDAQ:TSLA), Xoma Corp (NASDAQ:XOMA), Walt Disney …

Insider Selling Update: XOMA Corp, Bank of America Corp, Palo Alto Networks Inc

Recently, various executives have taken part in insider selling activity for the stocks of XOMA Corp (NASDAQ:XOMA), Bank of America Corp (NYSE:BAC), and Palo Alto Networks Inc …

Biotech Beat: XOMA Corp (XOMA), Synergy Pharmaceuticals Inc (SGYP), MannKind Corporation (MNKD), CIGNA Corporation (CI)

XOMA Corp Stock Starts To Recover XOMA Corp (NASDAQ:XOMA) had an incredibly rough day in the market yesterday. After announcing that a recent Phase 3 …

Cowen Heads to Sidelines on XOMA Corp as EYEGUARD-B Fails

In a research report released today, Cowen analyst Phil Nadeau downgraded shares of XOMA Corp (NASDAQ:XOMA) from an Outperform to a Market Perform rating, …

Wedbush Slashes Price Target For XOMA Corp But Remains Positive Following Failed Phase 3 Eyeguard-B Study

Xoma Ltd (NASDAQ:XOMA) shares are dropping 76.56% to $1.

Company Update (NASDAQ:XOMA): XOMA Corp Announces Results From Phase 3 EYEGUARD(TM)-B Study

XOMA Corp (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the Phase 3 EYEGUARD-B study of gevokizumab in patients …

Analysts Bullish on XOMA Corp (XOMA) While Awaiting Trial Results

Investors are patiently awaiting the results of XOMA Corp’s (NASDAQ:XOMA) EYEGUARD B Phase III trial. Shares of the company last closed at $4.

Cowen Reiterates Outperform on XOMA Corp Ahead of EYEGUARD-B Trial Results

Cowen analyst Phil Nadeau weighed in today with a few insights on XOMA Corp (NASDAQ:XOMA), as data from gevokizumab’s EYEGUARD-B trial is expected over the next couple of weeks. This program …

Biopharmaceutical Summer Highlights: Intercept Pharmaceuticals Inc (ICPT), Receptos Inc (RCPT), and XOMA Corp (XOMA)

Last week, Liana Moussatos of Wedbush released a report highlighting a list of upcoming catalysts for biopharmaceutical companies. Specifically, she noted forthcoming events …

Wedbush Reiterates Outperform on XOMA Corp Following Orphan Drug Status

In a research report published Tuesday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on XOMA Corp (NASDAQ:XOMA) with a price target of $17, after …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts